Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK NICE Changes Mind On Ocrevus After Roche Drops Price

Executive Summary

Health technology assessment body NICE has changed its mind about the use of Ocrevus for treating primary progressive multiple sclerosis after Roche offered a lower price for the drug.

You may also be interested in...

NHS England Hails Biggest CAR-T Uptake In Europe

Pharma must “speak the same language” as the National Health Service for “transactable” negotiations.

NHS England Offers ‘Improved’ Orkambi Deal, But Vertex Lukewarm

The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.

Roche Wants More Flexibility For UK’s NICE To Consider Indication-Based Pricing

Roche is calling for HTA body NICE to have greater flexibility on indication-based pricing.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts